Comments
GSK to go hostile with $2.6 billion Human Genome tender
09.05.2012. | LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board....
